spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  NGX-4010 

 HSMN NewsFeed - 2 Jun 2009
NeurogesX Receives FDA Orphan Drug Designation for Qutenza(TM) for Treatment of Postherpetic Neuralgia
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 21 May 2009
NeurogesX Receives European Commission Approval for Qutenza(TM)
Biopharmaceuticals Drug Delivery Regulatory
 HSMN NewsFeed - 19 Mar 2009
NeurogesX' Qutenza(TM) (NGX-4010) Receives Positive Committee Recommendation in European Union
Biopharmaceuticals Pain Management Regulatory
 HSMN NewsFeed - 22 Oct 2008
NeurogesX Submits NDA for NGX-4010 Dermal Capsaicin Patch for Treatment of Postherpetic Neuralgia (PHN)
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 9 Oct 2007
NeurogesX Expands Senior Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Sep 2007
NeurogesX' NGX-4010 MAA Filed and Accepted for Review by EMEA for Treatment of Peripheral Neuropathic Pain
Biopharmaceuticals Drug Delivery Regulatory
 HSMN NewsFeed - 5 Sep 2007
NeurogesX Appoints New Director to the Board
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Sep 2007
NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
Biopharmaceuticals Pain Management
 HSMN NewsFeed - 11 Jun 2007
NeurogesX Completes Enrollment in Phase 3 Clinical Trial for Postherpetic Neuralgia
Biopharmaceuticals
 HSMN NewsFeed - 7 Jun 2007
NeurogesX Announces Presentation of Positive Phase 3 Clinical Data at the Second International Congress on Neuropathic Pain Meeting (NeuPSIG)
Biopharmaceuticals
 HSMN NewsFeed - 29 May 2007
NeurogesX Appoints BioMarin CEO Bienaime as Chairman
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Oct 2006
NeurogesX Phase 3 Study in Post-Herpetic Neuralgia Meets Primary Endpoint
Biopharmaceuticals
 HSMN NewsFeed - 6 Sep 2006
NeurogesX Extension Study Indicates Repeat Treatment with Transacin Provides Prolonged Pain Reduction in HIV-Associated Neuropathy
Biopharmaceuticals
Return to NewsFeed  

 Additional items found! 10

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 10 additional stories matching:
NGX-4010
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.